Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106420 | 0.72 | LMNA (0.39) | LMNAGAAADRA1DADRA1AADRA1B | |
| SCHEMBL1326671 | 0.70 | LMNA (0.38) | LMNAGAAADRA1DADRA1AADRA1B | |
| SCHEMBL24577788 | 0.69 | POLB (0.38) | LMNAGAAADRA1DADRA1AADRA1B | |
| SCHEMBL30984513 | 0.69 | LMNA (0.37) | LMNAGAAADRA1DADRA1AADRA1B | |
| SCHEMBL545962 | 0.67 | ADRA1A (0.39) | LMNAGAAADRA1DADRA1AADRA1B | |
| SCHEMBL6692977 | 0.67 | OPRD1 (0.41) | LMNAADRA1DADRA1AADRA1B | |
| SCHEMBL327601 | 0.67 | OPRD1 (0.41) | LMNAADRA1DADRA1AADRA1B | |
| SCHEMBL290880 | 0.67 | — | — | |
| SCHEMBL3970107 | 0.67 | OPRD1 (0.41) | LMNAADRA1DADRA1AADRA1B | |
| SCHEMBL9345878 | 0.66 | LMNA (0.39) | LMNAGAAADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558955-B1 | BENZISOTHIAZOLE, ISOTHIAZOLO[3,4-B]PYRIDINE, QUINAZOLINE, PHTHALAZINE, PYRIDO[2,3-D]PYRIDAZINE AND PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS FOR TREATING LUNG, PANCREATIC OR COLORECTAL CANCER | AMGEN INC (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-2348010-B1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | NIPPON SODA CO (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-8481774-B2 | Method for producing tetrafluoro compound | NIPPON SODA CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8481774-B2 | Method for producing tetrafluoro compound | NIPPON SODA CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-2348010-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | Nippon Soda Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | NIPPON SODA CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | NIPPON SODA CO., LTD. (JP) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178323-A1 | METHOD FOR PRODUCING TETRAFLUORO COMPOUND | F9, CA9, TAF9 | LMNA 4472/4885GAA 3766/4885ADRA1D 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.